Inhalation

Advisory - Ombrelle Garnier Complete Dry Mist Spray sunscreen recalled due to elevated benzene levels

Friday, October 15, 2021 - 11:05pm

Product:Ombrelle Garnier Complete Dry Mist Spray sunscreen, SPF 30 and SPF 60 (DIN02415313 and DIN 02415402)

Key Points: 
  • Product:Ombrelle Garnier Complete Dry Mist Spray sunscreen, SPF 30 and SPF 60 (DIN02415313 and DIN 02415402)
    Issue:Ombrelle Canada is recalling all lotsdue to elevated levels of benzene, which may pose serious health risks.
  • Ombrelle Canada is recalling all lots of Ombrelle Garnier Complete Dry Mist Spray sunscreen, SPF30 and SPF 60, due to elevated levels of benzene.
  • Frequent and long-term exposure (e.g., through the skin and by inhalation) to elevated levels of benzene may pose serious health risks.
  • Immediate signs of exposure to elevated levels of benzene include drowsiness, dizziness, rapid or irregular heartbeat, and headaches.

Global Autoimmune Disorder Drug Delivery Devices Market 2021-2026 - Home Care Settings Will Dominate due to Longer Wait Times in Hospitals - ResearchAndMarkets.com

Friday, October 15, 2021 - 12:19pm

The outbreak of the COVID-19 pandemic made a relatively positive impact on the Global Autoimmune Disorder Drug Delivery Devices Market.

Key Points: 
  • The outbreak of the COVID-19 pandemic made a relatively positive impact on the Global Autoimmune Disorder Drug Delivery Devices Market.
  • What are the overall market statistics or market estimates (Market Overview, Market Size - By Value, Forecast Numbers, Market Segmentation, Market Shares) of the Global Autoimmune Disorder Drug Delivery Devices Market?
  • What are the key innovations, opportunities, current & future trends, and regulations in the Global Autoimmune Disorder Drug Delivery Devices Market?
  • What are the key results derived from the market surveys conducted during the Global Autoimmune Disorder Drug Delivery Devices Market study?

DGAP-News: Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF(TM)

Thursday, October 14, 2021 - 2:29pm

Since the beginning of the clinical development program in late-2016, QIXLEEF(TM) strictly adhered to and complied with the regulatory requirements of a prescription drug.

Key Points: 
  • Since the beginning of the clinical development program in late-2016, QIXLEEF(TM) strictly adhered to and complied with the regulatory requirements of a prescription drug.
  • Having a global drug development strategy ensures economy of scale and lower cost of drug development to shareholders.
  • The REBORN(c) clinical strategy provides the fastest and lowest cost development program to bring QIXLEEF(TM) to the market.
  • Guy Chamberland, CEO and CRO commented, "Our team has made significant progress in bringing QIXLEEF(TM) to a late clinical development stage.

Streamline Innovations Launches Into Middle East Market, Enters Strategic Partnership with EMDAD in United Arab Emirates

Thursday, October 14, 2021 - 12:00pm

Under the terms of the Agency Agreement, EMDAD will represent Streamline in the U.A.E.

Key Points: 
  • Under the terms of the Agency Agreement, EMDAD will represent Streamline in the U.A.E.
  • and other oil producing nations in the Middle East are transitioning to more sustainable and environmentally friendly operational practices.
  • Streamline technology destroys H2S and converts it into Simple Elemental Sulfur, which is listed with the Organic Material Review Institute (OMRI) for use in Organic Production.
  • The establishment of this relationship with Streamline Innovations comes at an opportune time for both our clients and our company, said Mohammed Juma Al Bawardi, Chairman of EMDAD.

Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™

Thursday, October 14, 2021 - 11:30am

Since the beginning of the clinical development program in late-2016, QIXLEEF strictly adhered to and complied with the regulatory requirements of a prescription drug.

Key Points: 
  • Since the beginning of the clinical development program in late-2016, QIXLEEF strictly adhered to and complied with the regulatory requirements of a prescription drug.
  • The Company completed two Phase 1 clinical trials in healthy volunteers to assess the safety profile, including cardiovascular, pharmacodynamics and pharmacokinetics, of smoked and vaporized QIXLEEF.
  • The REBORN clinical strategy provides the fastest and lowest cost development program to bring QIXLEEF to the market.
  • Guy Chamberland, CEO and CRO commented, "Our team has made significant progress in bringing QIXLEEF to a late clinical development stage.

Cybin Files an International Patent Application Covering Psychedelic Delivery Methods

Tuesday, October 12, 2021 - 12:00pm

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods.

Key Points: 
  • Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods.
  • The application, governed by the Patent Cooperation Treaty (PCT), brings the potential to obtain patent coverage in 153 countries.
  • The Company believes that the delivery of psychedelic medications using inhalation may overcome key obstacles encountered by traditional oral drug administration.
  • Specifically, the Company expects inhalation delivery to facilitate optimized psychedelic session timing compared to oral administration of the same compounds, lower doses of psychedelic therapeutics while preserving efficacy, and providing health care providers with more control during psychedelic sessions.

DGAP-News: APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01

Tuesday, October 12, 2021 - 8:02am

Romana Gugenberger PhD, CMSO of APEIRON Biologics AG, explains: "The start of this company sponsored trial for APN01 is a vital next step in our development approach.

Key Points: 
  • Romana Gugenberger PhD, CMSO of APEIRON Biologics AG, explains: "The start of this company sponsored trial for APN01 is a vital next step in our development approach.
  • Peter Llewellyn-Davies, CEO of APEIRON Biologics AG, adds: "We desperately need an effective treatment for COVID-19 and an inhaled application is an important strategic milestone for APEIRON.
  • This is the third clinical trial dedicated to the multi-armed initiative of developing APN01 into vital therapy options in COVID-19.
  • APEIRON Biologics' projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.

33,000 Pet Oxygen Masks Donated and Counting: Calvert County Stations to Receive 90 Pet Oxygen Masks

Friday, October 8, 2021 - 8:12pm

Since Project Breathe's inception in 2006, over 33,000 masks have been donated to first responders and now the company is giving more.

Key Points: 
  • Since Project Breathe's inception in 2006, over 33,000 masks have been donated to first responders and now the company is giving more.
  • "We want to ensure that every fire department and rescue unitacross the U.S. and Canada areequipped with life-saving pet oxygen masks."
  • Fire departments can request pet oxygen mask kit donations here .For additional information orquestions,customers can call their local Invisible Fence dealeror visit InvisibleFence.com .
  • Invisible Fence pioneered the pet containment industry in 1973, making it their mission to provide safe boundaries inside and outsideofthehome.

Aegle Launches Pre-sales of N95s with Ascend's Acteev® Antimicrobial Technology

Friday, October 8, 2021 - 6:53pm

Aegle and Acteev experts will be available in booth 2048 to discuss the technologies.

Key Points: 
  • Aegle and Acteev experts will be available in booth 2048 to discuss the technologies.
  • Aegle uses proprietary authentication and traceability technology to prevent counterfeiting, guarantee testing performance, and ensure supply-chain security.
  • With the abundance of counterfeit masks on the market, it's smart to rely on the technological advantages built into each Aegle mask.
  • We are thrilled to work with Acteev to help keep Americans safe," says Andy Moy, Partner at Aegle.

Advisory - Certain lots of Tinactin aerosol sprays for athlete's foot recalled

Tuesday, October 5, 2021 - 11:55pm

Product:Tinactin Aerosol Powder, Tinactin Chill Deodorant Powder Spray, and Tinactin Chill Liquid Spray

Key Points: 
  • Product:Tinactin Aerosol Powder, Tinactin Chill Deodorant Powder Spray, and Tinactin Chill Liquid Spray
    Issue:Bayer Inc. is recalling certain lots due to elevated levels of benzene, which may pose serious health risks.
  • Bayer Inc. is recalling six lots (lot numbers beginning with TN) of Tinactin Aerosol Powder, Tinactin Chill Deodorant Powder Spray, and Tinactin Chill Liquid Spray due to elevated levels of benzene.
  • Frequent and long-term exposure (e.g., through the skin and by inhalation) to elevated levels of benzene may pose serious health risks.
  • These sprays are antifungal products used for the treatment and prevention of athlete's foot.